Four insights:
1. The company signed a private label agreement with a biologics company to enter the cellular bone graft market.
2. Camber Spine’s allogenic bone matrix product, Scylla, consists of spine-derived cells to support the osteogenic healing process.
3. Scylla features an osteoconductive 3D scaffold with cortical and cancellous properties and demineralized bone scaffold with osteoinductive potential.
4. Zion Market Research reported the global bone grafts and substitutes market to be a $2.7 billion industry, predicted to grow to $4.2 billion by 2026.
More articles on biologics:
Dr. Robert Brady: Robotics in spinal fusion and how the trend will develop in spine
Orthofix names DePuy, Medtronic, Biomet veteran the next CEO
Medicrea receives FDA approval for new screw device
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
